Note for Clinicians: While “leukoderma” is a general term for depigmentation, in clinical practice, it most commonly refers to Vitiligo. This review focuses on Vitilio as the primary differential diagnosis for acquired leukoderma.

1. Pathophysiology and Etiology

Vitiligo is an acquired pigmentary disorder characterized by the progressive destruction of melanocytes within the basal layer of the epidermis. While the exact mechanism remains a subject of ongoing research, current evidence supports a multifactorial autoimmune etiology.

• Autoimmune Mechanism: The prevailing theory involves T-cell-mediated destruction of melanocytes. CD8+ cytotoxic T-cells recognize melanocyte-specific antigens (such as MART-1). This is supported by the high prevalence of co-occurring autoimmune endocrinopathies.
• Oxidative Stress Theory: Accumulation of reactive oxygen species (ROS) within melanocytes leads to oxidative damage, impairing melanocyte function and triggering apoptosis.
• Neurogenic Component: Evidence suggests that perilesional nerve endings release neuropeptides (e.g., substance P), which may trigger inflammatory responses, potentially explaining the “segmental” subtype of vitiligo.
• Genetic Predisposition: While not strictly Mendelian, polygenic inheritance is evident. Polymorphisms in genes such as HLA-A, HLA-B, and HLA-DR are significantly associated with increased risk.

2. Clinical Classification and Presentation

Accurate classification is critical for determining prognosis and treatment intensity.

Clinical Subtypes:

1. Non-Segmental Vitiligo (NSV): The most common form. It is typically bilateral and symmetrical.
   • Focal: Limited to one or a few areas.
   • Generalized: Widespread involvement; often follows a “stable” or “progressive” course.
2. Segmental Vitiligo (SV): Unilateral, often following a dermatomal distribution. It typically has an earlier onset and a more rapid progression in the initial phase, followed by stability. It is less likely to respond to systemic immunosuppression than NSV.

Differential Diagnosis (The “Leukoderma” Spectrum):

To avoid misdiagnosis, clinicians must differentiate vitiligo from:

• Tinea Versicolor: Fungal infection; characterized by fine scale and positive KOH prep (spaghetti and meatballs appearance).
• **Pityriasis Alba:** Common in atopic patients; presents with ill-defined hypopigmented patches rather than complete depigmentation.
• Idiopathic Guttate Hypomelanosis (IGH): Small, “confetti-like” white macules, typically on sun-exposed areas in older adults.
• Lichen Sclerosus: Presents with atrophy and scarring; requires biopsy to rule out malignancy risk.
• Post-Inflammatory Hypopigmentation: Resulting from resolved trauma, burns, or dermatitis.

3. Diagnostic Workup

• Physical Examination: Assessment of lesion margins (typically sharp in vitiligo) and distribution.
• Wood’【s】 Lamp Examination: Essential for confirming depigmentation. Under UV light (365 nm), vitiligo lesions exhibit a characteristic bright white fluorescence due to the absence of melanin, helping to distinguish it from hypopigmentary disorders.
• Laboratory Investigations: Because of the autoimmune link, clinicians should screen for:
  • Thyroid Function Tests (TSH, Free T4): To rule out Hashimoto’s thyroiditis.
  • Vitamin B12 levels: Often deficient in patients with vitiligo.
  • ANA Screening: If systemic autoimmune disease is suspected.

4. Evidence-Based Management Strategies

Treatment should be individualized based on the subtype, stability of lesions, and patient’s psychosocial impact.

First-Line Pharmacotherapy (Non-Segmental Vitiligo):

1. Topical Corticosteroids (TCS): High-potency TCS (e.g., Clobetasol) are used to reduce inflammation and suppress T-cell activity. Caution: Long-term use carries risks of skin atrophy and striae.
2. Topical Calcineurin Inhibitors (TCI): Tacrolimus (0.1%) or Pimecrolimus are preferred for sensitive areas (face, neck) to avoid steroid-induced atrophy. They are highly effective in stabilizing disease.

Phototherapy (The Gold Standard for Generalized Vitiligo):

• Narrowband UVB (NB-UVB): Currently considered the first-line phototherapy due to its efficacy and lower risk of erythema compared to broad-spectrum UVB. It works by inducing melanocyte proliferation and stimulating repigmentation from hair follicles.
• Excimer Laser: Highly effective for localized, stable lesions; allows for targeted treatment without exposing surrounding healthy skin.

Combination Therapy:

The most robust clinical outcomes are often seen when combining TCI + NB-UVB. This synergistic approach addresses both the inflammatory component and the stimulation of melanocyte migration.

Advanced/Refractory Options:

• JAK Inhibitors: The emergence of topical Janus Kinase (JAK) inhibitors (e.g., Ruxolitinib) represents a paradigm shift. By inhibiting the cytokine signaling pathways involved in melanocyte destruction, they offer a targeted approach with potentially fewer side effects than steroids.
• Depigmentation: Reserved for patients with widespread disease (>50% body surface area) where repigmentation is unlikely. This involves using agents like Monobenzyl Ether of Hydroquinone (MBEH) to achieve a uniform skin tone.
• Surgical Intervention: Skin grafting or melanocyte-keratinocyte separation (MKCE) is indicated only for stable, non-progressive vitiligo where topical/phototherapy has failed.

5. Clinical Pearls & Patient Counseling

• Stability Assessment: A lesion is considered “stable” if there has been no change in size or color for at least 6–12 months. Treatment efficacy (especially surgery) depends heavily on this distinction.
• Psychosocial Impact: Vitiligo carries a significant burden of psychological distress. Screening for depression and anxiety is recommended.
• Sun Protection: Patients must be educated on the loss of natural UV protection in depigmented areas, increasing the risk of solar damage and skin cancer. Daily SPF 30+ is mandatory.